HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: A tissue microarray study of 814 archival specimens

APMIS

Volumn 117, Issue 10, 2009, Pages 737-745

  Lesnikova, Iana ^a   Lidang, Marianne ^b   Hamilton Dutoit, Stephen ^a   Koch, Jørn ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cervical neoplasia; HER2 neu; Immunohistochemistry; In situ hybridization; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR;

FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 70349307488     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02531.x     Document Type: Article

References (31)

1. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006 6 : 753 763.
2. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001 61 (SUPPL. 2 1 13.
3. Slamon DJ, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244 : 707 712.
4. Brumm C, Rivière A, Wilckens C, Löning T. Immunohistochemical investigation and northern blot analysis of c-erB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. Virchows Arch A Pathol Anat Histopathol 1990 417 : 477 484.
5. Hale RJ, et al. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 1992 45 : 594 596.
6. Hunt CR, et al. c-erbB-3 proto-oncogene expression in uterine cervical carcinoma. Int J Gynecol Cancer 1995 5 : 282 285.
7. Kristensen GB, et al. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996 78 : 433 440.
8. Mandai M, et al. Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 1995 75 : 2523 2529.
9. Ndubisi B, et al. The prognostic value of HER-2/neu oncogene in cervical cancer. Ann Clin Lab Sci 1997 27 : 396 401.
10. Rosty C, et al. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int J Gynecol Pathol 2004 23 : 13 7.
11. Niibe Y, et al. Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer 2003 13 : 849 855.
12. Perez-Regadera J, et al. Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer. Oncology 2009 76 : 133 141.
13. Bellone S, et al. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol 2003 91 : 231 240.
14. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999 112 (1 SUPPL. 1 S53 67.
15. Pauletti G, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000 18 : 3651 3664.
16. Tsuda H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 2001 92 : 2965 2974.
17. Tanner M, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000 157 : 1467 1472.
18. Fuchs I, et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 2007 27 : 959 963.
19. Herrington CS, et al. Loss of sequences on the short arm of chromosome 17 is a late event in squamous carcinoma of the cervix. Mol Pathol 2001 54 : 160 164.
20. Mark HF, et al. HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization. Genet Test 1999 3 : 237 242.
21. Sharma A, et al. Frequent amplification of C-erbB2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections. Oncology 1999 56 : 83 7.
22. Kononen J, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998 4 : 844 847.
23. Powell WC, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol 2007 15 : 94 102.
24. Nishioka T, et al. Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. J Cancer Res Clin Oncol 1999 125 : 96 100.
25. Oka K, Nakano T, Arai T. c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 1994 73 : 664 671.
26. Press MF, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994 54 : 2771 2777.
27. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008 26 : 5630 5637.
28. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000 80 : 1943 1949.
29. Loring P, et al. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol 2005 13 : 194 200.
30. Kallioniemi O, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992 89 : 5321 5325.
31. O-charoenrat P, et al. C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 2002 38 : 73 80.